EMOLYTIC uremic syndrome (HUS) consists of nonimmune hemolytic anemia, thrombocytopenia, and renal failure caused by platelet thrombi in the microcirculation of the kidney and other organs. The characteristic lesion, thrombotic microangiopathy, consists of vessel wall thickening, with swelling and detachment of endothelial cells from the basement membrane and accumulation of fluffy material in the subendothelium. 1 HUS usually manifests as an acute disease, with gastrointestinal or respiratory tract prodromes, that spontaneously recovers without sequelae in 80% to 90% of cases (ie, most cases of childhood HUS) or after plasma infusion or exchange (ie, adult or severe forms of HUS). Environmental factors, drugs, or infective agents such as verotoxin-producing Escherichia coli trigger typical HUS; systemic immune disorders or cancer also may cause the disease. 2 These forms of HUS may subside when the underlying condition has been treated or removed. Rare forms occur and are often familial, with both autosomal recessive and dominant modes of inheritance.
[1]
V. V. van Hinsbergh,et al.
Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome.
,
2000,
Blood.
[2]
G. Remuzzi,et al.
Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura.
,
1999,
Journal of the American Society of Nephrology : JASN.
[3]
J. Goodship,et al.
Genetic studies into inherited and sporadic hemolytic uremic syndrome.
,
1998,
Kidney international.
[4]
G. Remuzzi,et al.
Increased nitric oxide formation in recurrent thrombotic microangiopathies: a possible mediator of microvascular injury.
,
1996,
American journal of kidney diseases : the official journal of the National Kidney Foundation.